nabumetone has been researched along with Osteoarthritis of Knee in 7 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study found no significant differences in pain relief or tolerability between treatment with SAMe or nabumetone over 8 weeks in Korean patients with knee OA." | 5.14 | Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. ( Cha, HS; Kim, J; Koh, EM; Lee, CK; Lee, EY; Lee, KH; Lee, YJ; Ryu, H; Song, YW; Yoo, B, 2009) |
| " Rofecoxib at a dosage of 12." | 2.72 | Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. ( Geba, GP; Messner, RP; Najarian, DK; Petruschke, RA; Polis, AB; Storms, WW; Tershakovec, AM; Weaver, AL, 2006) |
| " The main safety measure was adverse events during the 6 weeks of treatment." | 2.71 | Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. ( Baraf, HS; Cohen, SB; Dixon, ME; Geba, GP; Green, JA; Greenwald, MW; Kivitz, AJ; Matsumoto, AK; Moidel, RA; Najarian, DK; Petruschke, RA; Polis, AB, 2004) |
| "Rofecoxib treatment, with its faster onset of OA efficacy and lower rates of related discontinuations, might provide efficacy advantages in the treatment of OA pain." | 2.71 | Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. ( Battisti, WP; Geba, GP; Katz, NP; Kivitz, AJ; Matsumoto, AK; Polis, AB; Weaver, AL, 2004) |
| "Naproxen CR is an effective and tolerable drug in the treatment of knee OA." | 2.70 | Comparison of the efficacy and safety of naproxen CR and nabumetone in the treatment of patients with osteoarthritis of the knee. ( Cha, HS; Jeon, CH; Kim, JS; Koh, EM; Koh, JH; Lee, CK, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, J | 1 |
| Lee, EY | 1 |
| Koh, EM | 2 |
| Cha, HS | 2 |
| Yoo, B | 1 |
| Lee, CK | 2 |
| Lee, YJ | 1 |
| Ryu, H | 1 |
| Lee, KH | 1 |
| Song, YW | 1 |
| Kivitz, AJ | 2 |
| Greenwald, MW | 1 |
| Cohen, SB | 1 |
| Polis, AB | 3 |
| Najarian, DK | 2 |
| Dixon, ME | 1 |
| Moidel, RA | 1 |
| Green, JA | 1 |
| Baraf, HS | 1 |
| Petruschke, RA | 2 |
| Matsumoto, AK | 2 |
| Geba, GP | 3 |
| Battisti, WP | 1 |
| Katz, NP | 1 |
| Weaver, AL | 2 |
| Messner, RP | 1 |
| Storms, WW | 1 |
| Tershakovec, AM | 1 |
| Zhao, SZ | 1 |
| Dedhiya, SD | 1 |
| Bocanegra, TS | 1 |
| Fort, JG | 1 |
| Kuss, ME | 1 |
| Rush, SM | 1 |
| Becvár, R | 1 |
| Urbanová, Z | 1 |
| Vlasáková, V | 1 |
| Vítová, J | 1 |
| Rybár, I | 1 |
| Maldyk, H | 1 |
| Filipowicz-Sosnowska, A | 1 |
| Bernacka, K | 1 |
| Mackiewicz, S | 1 |
| Gömör, B | 1 |
| Rojkovich, B | 1 |
| Siro, B | 1 |
| Bereczki, J | 1 |
| Toth, K | 1 |
| Sukenik, S | 1 |
| Green, L | 1 |
| Ehrenfeld, M | 1 |
| Pavelka, K | 1 |
| Koh, JH | 1 |
| Jeon, CH | 1 |
| Kim, JS | 1 |
7 trials available for nabumetone and Osteoarthritis of Knee
| Article | Year |
|---|---|
Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients.
Topics: Aged; Analgesics; Anti-Inflammatory Agents; Asian People; Butanones; Double-Blind Method; Female; Hu | 2009 |
Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase I | 2004 |
Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Butano | 2004 |
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase 2 Inhibitor | 2006 |
Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Female; Humans; Male; Middle Aged; Nabumet | 1999 |
Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Dicl | 1999 |
Comparison of the efficacy and safety of naproxen CR and nabumetone in the treatment of patients with osteoarthritis of the knee.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Constipation; | 2001 |